Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.46 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.42 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.42 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.39 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888152 | 0.98 | CYP1A2 (0.53) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL22065483 | 0.86 | CYP1A2 (0.44) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL8973710 | 0.81 | CA12 (0.40) | CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL20025625 | 0.81 | MIF (0.52) | MAOAMAOBMIFALDH1A1TRPA1 | |
| SCHEMBL10592677 | 0.80 | MIF (0.47) | CYP1A2CYP2D6SIGMAR1MAOAMAOB | |
| SCHEMBL3830223 | 0.76 | CYP1A2 (0.82) | CYP1A2CYP2D6ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2046670 | 0.76 | MIF (0.65) | SIGMAR1MIFALDH1A1TRPA1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28283794 | 0.76 | ALDH1A1 (0.41) | CYP1A2CYP2D6TAAR1MAOAMAOB | |
| SCHEMBL11322654 | 0.75 | KCNH2 (0.43) | CYP1A2CYP2D6SIGMAR1MIFALDH1A1 | |
| SCHEMBL6238480 | 0.74 | CYP1A2 (0.55) | CYP1A2CYP2D6SIGMAR1TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210146006-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | TRUELASTIN LABORATORIES, INC. | 2021-05-20 | — | — | US | claimed |
| US-10583218-B2 | Composite containing collagen and elastin as a dermal expander and tissue filler | HANCOCK JAFFE LABORATORIES AESTHETICS, INC. (US) | 2020-03-10 | — | — | US | claimed |
| US-20120010146-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | HANCOCK JAFFE LABORATORIES, INC. (US) | 2012-01-12 | — | — | US | claimed |
| WO-2010053918-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | HANCOCK JAFFE LABORATORIES, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| EP-1305064-B1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS INC (US) | 2008-04-23 | — | — | EP | claimed |
| EP-1305064-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| US-6548081-B2 | Hyaluronic acid derivative is an N-acylurea that results from crosslinking hyaluronic acid with a multifunctional carbodiimide. reducing post-operative adhesion of tissues. | ANIKA THERAPEUTICS, INC. | 2003-04-15 | — | — | US | claimed |
| US-20020071855-A1 | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers | ANIKA THERAPEUTICS, INC | 2002-06-13 | — | — | US | claimed |
| WO-2002009792-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| EP-3448394-B1 | COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION | ANIKA THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11541075-B2 | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid | ANIKA THERAPEUTICS, INC. | 2023-01-03 | — | — | US | disclosed |
| US-20210213043-A1 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210146006-A1 | COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER | TRUELASTIN LABORATORIES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10583218-B2 | Composite containing collagen and elastin as a dermal expander and tissue filler | HANCOCK JAFFE LABORATORIES AESTHETICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| WO-2007070547-A2 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070617-A1 | BIOABSORBABLE IMPLANT OF HYALURONIC ACID DERIVATIVE FOR TREATMENT OF OSTEOCHONDRAL AND CHONDRAL DEFECTS | ANIKA THERAPEUTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1305064-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6548081-B2 | Hyaluronic acid derivative is an N-acylurea that results from crosslinking hyaluronic acid with a multifunctional carbodiimide. reducing post-operative adhesion of tissues. | ANIKA THERAPEUTICS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020071855-A1 | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers | ANIKA THERAPEUTICS, INC | 2002-06-13 | — | — | US | disclosed |
| WO-2002009792-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541075-B2 | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid | CD44, APEH, IDE | SIGMAR1 1468/4885MAOA 1868/4885MAOB 1894/4885 |
| US-20210213043-A1 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID | CD44, APEH, IDE | SIGMAR1 1468/4885MAOA 1868/4885MAOB 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.